首页> Annals of oncology : official journal of the European Society for Medical Oncology> Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.

导出 LinkOut

翻译打印收藏纠错

第一作者： A,Raimondi

第一单位： Department of Medical Oncology, Istituto Nazionale Tumori IRCCS Milan, Milan, USA.

作者： A,Raimondi ^[1] ; S,Lonardi ^[2] ; S,Murgioni ^[3] ; G G,Cardellino ^[4] ; S,Tamberi ^[5] ; A,Strippoli ^[6] ; F,Palermo ^[1] ; G,De Manzoni ^[7] ; M,Bencivenga ^[7] ; A,Bittoni ^[8] ; C,Chiodoni ^[9] ; D,Lorenzini ^[10] ; K,Todoerti ^[10] ; P,Manca ^[1] ; S,Sangaletti ^[9] ; M,Prisciandaro ^[1] ; G,Randon ^[1] ; F,Nichetti ^[1] ; F,Bergamo ^[3] ; S,Brich ^[10] ; A,Belfiore ^[10] ; A,Bertolotti ^[10] ; D,Stetco ^[10] ; A,Guidi ^[10] ; T,Torelli ^[10] ; A,Vingiani ^[10] ; R P,Joshi ^[11] ; M,Khoshdeli ^[11] ; N,Beaubier ^[11] ; M C,Stumpe ^[11] ; F,Nappo ^[3] ; A G,Leone ^[1] ; C C,Pircher ^[1] ; G,Leoncini ^[10] ; G,Sabella ^[10] ; L,Airo' Farulla ^[12] ; A,Alessi ^[12] ; F,Morano ^[1] ; A,Martinetti ^[1] ; M,Niger ^[1] ; M,Fassan ^[13] ; M,Di Maio ^[14] ; K,Kaneva ^[11] ; M,Milione ^[10] ; H,Nimeiri ^[11] ; C,Sposito ^[15] ; L,Agnelli ^[16] ; V,Mazzaferro ^[15] ; M,Di Bartolomeo ^[1] ; F,Pietrantonio ^[17]

作者单位： Department of Medical Oncology, Istituto Nazionale Tumori IRCCS Milan, Milan, USA. ^[1] Medical Oncology 3, Veneto Institute of Oncology IOV - IRCCS, Padua, USA. ^[2] Medical Oncology 1, Veneto Institute of Oncology IOV - IRCCS, Padua, USA. ^[3] Department of Oncology, Presidio Ospedaliero "Santa Maria della Misericordia"-ASUFC, Udine, USA. ^[4] Oncology Unit, Ravenna Hospital, AUSL Romagna, Ravenna, USA. ^[5] Medical Oncology Unit, Policlinico Universitario A. Gemelli, Rome, USA. ^[6] Department of Surgery, Azienda Ospedaliero Universitaria Integrata di Verona-Borgo Trento, Verona, USA. ^[7] Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", Meldola, USA. ^[8] Molecular Immunology Unit, Department of Experimental Oncology, Fondazione IRCCS Istituto Nazionale Tumori, Milan, USA. ^[9] Department of Diagnostic Innovation, Istituto Nazionale Tumori IRCCS, Milan, USA. ^[10] Tempus, Chicago, USA. ^[11] Division of Nuclear Medicine, Istituto Nazionale Tumori IRCCS Milan, Milan, Italy. ^[12] School of Medicine and Surgery, University of Padua, Padua, Italy. ^[13] Department of Oncology, University of Turin, at Le Molinette Hospital, Turin, Italy. ^[14] Department of Oncology, University of Milan and G.I. Surgery, Istituto Nazionale Tumori IRCCS Milan, Milan, Italy. ^[15] Department of Medical Oncology, Istituto Nazionale Tumori IRCCS Milan, Milan, USA; Department of Diagnostic Innovation, Istituto Nazionale Tumori IRCCS, Milan, USA. ^[16] Department of Medical Oncology, Istituto Nazionale Tumori IRCCS Milan, Milan, USA. Electronic address: filippo.pietrantonio@istitutotumori.mi.it. ^[17]

关键词 gastric cancer immunotherapy microsatellite instability non-operative management